Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 27

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 27
---
 to determine to delist our Depositary Shares, investors could lose all or
part of their investment and our ability to raise additional capital through the public or private sale of equity securities would be
adversely affected.

| 16 |

This offering may cause the price of our Depositary Shares to decline and fall below the minimum bid price requirement required by the NASDAQ Listing Rules, which could result in our Depositary Shares being delisted from The NASDAQ Capital Market. A delisting of our Depositary Shares from The NASDAQ Capital Market could adversely affect our ability to raise additional capital through the public or private sale of equity securities, the ability of investors to dispose of Depositary Shares or obtain accurate quotations as to the market value of our Depositary Shares and the price and value of our Depositary Shares.

Our
Depositary Shares are currently listed on The NASDAQ Capital Market. Continued listing of a security on The NASDAQ Capital Market is conditioned
upon compliance with various continued listing standards. In particular, the requirements for The NASDAQ Capital Market impose a minimum
$1.00 per share bid price requirement. To comply with this requirement, the closing price for our Depositary Shares must not fall below
$1.00 for a 30 consecutive trading day period. If we are unable to maintain a minimum closing price of $1.00 per Depositary Share for
the preceding 30 consecutive trading days, we will receive a deficiency letter from the staff of NASDAQ, or the Staff. The Staff may provide
us with a 180-calendar day grace period to regain compliance with the bid price requirement. If we are unable to regain compliance with
the bid price requirement within the 180-calendar day grace period or if no grace period is made available to us, we may be delisted from
The NASDAQ Capital Market unless we change the ratio of our Depositary Shares to Ordinary Shares; however, there can be no assurance that
we will be able to change the ratio of our Depositary Shares to Ordinary Shares or that, if we are able to change the ratio, changing
the ratio of our Depositary Shares to Ordinary Shares will allow us to regain compliance with the bid price requirement. We currently
do not have plans to change the ratio of our Depositary Shares to Ordinary Shares or to implement a reverse stock split with respect to
our Ordinary Shares.

Additionally,
in the event of a delisting notice, we would typically have an opportunity to appeal such decision to the NASDAQ Hearing Panel or take
other measures to